Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1994 Jul;7(3):303–310. doi: 10.1128/cmr.7.3.303

Malaria vaccine development.

T R Jones 1, S L Hoffman 1
PMCID: PMC358327  PMID: 7923051

Abstract

The malaria parasite life cycle presents several targets for attack, but these different parts of the life cycle are susceptible to different types of host immune response. For example, the sporozoite is most sensitive to immune antibody, while liver stage parasites can be eliminated by cytotoxic T lymphocytes. Attachment of merozoites to erythrocytes, on the other hand, can be blocked by antibody. Convincing experimental evidence shows that completely protective immunity to malaria can be induced. The challenge now is to design recombinant or synthetic vaccines that induce the right types of immune responses to specific life cycle stages. This requires the identification and characterization of B- and T-lymphocyte epitopes expressed by the parasite or by parasitized host cells. These epitopes must be incorporated into a delivery system that maximizes the interaction between the vaccine epitopes and the host immune system. Many epitopes from several parts of the life cycle are already characterized; development of multivalent vaccines, that is, vaccines which contain immunogens from more than one part of the life cycle, is a promising area for research efforts.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal A., Kumar S., Jaffe R., Hone D., Gross M., Sadoff J. Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med. 1990 Oct 1;172(4):1083–1090. doi: 10.1084/jem.172.4.1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ak M., Bower J. H., Hoffman S. L., Sedegah M., Lees A., Carter M., Beaudoin R. L., Charoenvit Y. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites. Infect Immun. 1993 Jun;61(6):2493–2497. doi: 10.1128/iai.61.6.2493-2497.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baird J. K., Basri H., Purnomo, Bangs M. J., Subianto B., Patchen L. C., Hoffman S. L. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991 May;44(5):547–552. doi: 10.4269/ajtmh.1991.44.547. [DOI] [PubMed] [Google Scholar]
  4. Ballou W. R., Hoffman S. L., Sherwood J. A., Hollingdale M. R., Neva F. A., Hockmeyer W. T., Gordon D. M., Schneider I., Wirtz R. A., Young J. F. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281. doi: 10.1016/s0140-6736(87)90540-x. [DOI] [PubMed] [Google Scholar]
  5. Barr P. J., Green K. M., Gibson H. L., Bathurst I. C., Quakyi I. A., Kaslow D. C. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med. 1991 Nov 1;174(5):1203–1208. doi: 10.1084/jem.174.5.1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Blackman M. J., Heidrich H. G., Donachie S., McBride J. S., Holder A. A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990 Jul 1;172(1):379–382. doi: 10.1084/jem.172.1.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990 Dec 1;172(6):1633–1641. doi: 10.1084/jem.172.6.1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burns J. M., Jr, Majarian W. R., Young J. F., Daly T. M., Long C. A. A protective monoclonal antibody recognizes an epitope in the carboxyl-terminal cysteine-rich domain in the precursor of the major merozoite surface antigen of the rodent malarial parasite, Plasmodium yoelii. J Immunol. 1989 Oct 15;143(8):2670–2676. [PubMed] [Google Scholar]
  9. Bzik D. J., Li W. B., Horii T., Inselburg J. Amino acid sequence of the serine-repeat antigen (SERA) of Plasmodium falciparum determined from cloned cDNA. Mol Biochem Parasitol. 1988 Sep;30(3):279–288. doi: 10.1016/0166-6851(88)90097-7. [DOI] [PubMed] [Google Scholar]
  10. COHEN S., McGREGOR I. A., CARRINGTON S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961 Nov 25;192:733–737. doi: 10.1038/192733a0. [DOI] [PubMed] [Google Scholar]
  11. Camus D., Hadley T. J. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science. 1985 Nov 1;230(4725):553–556. doi: 10.1126/science.3901257. [DOI] [PubMed] [Google Scholar]
  12. Charoenvit Y., Collins W. E., Jones T. R., Millet P., Yuan L., Campbell G. H., Beaudoin R. L., Broderson J. R., Hoffman S. L. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science. 1991 Feb 8;251(4994):668–671. doi: 10.1126/science.1704150. [DOI] [PubMed] [Google Scholar]
  13. Charoenvit Y., Leef M. F., Yuan L. F., Sedegah M., Beaudoin R. L. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun. 1987 Mar;55(3):604–608. doi: 10.1128/iai.55.3.604-608.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Charoenvit Y., Mellouk S., Cole C., Bechara R., Leef M. F., Sedegah M., Yuan L. F., Robey F. A., Beaudoin R. L., Hoffman S. L. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol. 1991 Feb 1;146(3):1020–1025. [PubMed] [Google Scholar]
  15. Clyde D. F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg. 1975 May;24(3):397–401. doi: 10.4269/ajtmh.1975.24.397. [DOI] [PubMed] [Google Scholar]
  16. Clyde D. F., Most H., McCarthy V. C., Vanderberg J. P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973 Sep;266(3):169–177. doi: 10.1097/00000441-197309000-00002. [DOI] [PubMed] [Google Scholar]
  17. Collins W. E., Anders R. F., Pappaioanou M., Campbell G. H., Brown G. V., Kemp D. J., Coppel R. L., Skinner J. C., Andrysiak P. M., Favaloro J. M. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature. 1986 Sep 18;323(6085):259–262. doi: 10.1038/323259a0. [DOI] [PubMed] [Google Scholar]
  18. Coppel R. L., Cowman A. F., Anders R. F., Bianco A. E., Saint R. B., Lingelbach K. R., Kemp D. J., Brown G. V. Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences. 1984 Aug 30-Sep 5Nature. 310(5980):789–792. doi: 10.1038/310789a0. [DOI] [PubMed] [Google Scholar]
  19. Daly T. M., Long C. A. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun. 1993 Jun;61(6):2462–2467. doi: 10.1128/iai.61.6.2462-2467.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dame J. B., Williams J. L., McCutchan T. F., Weber J. L., Wirtz R. A., Hockmeyer W. T., Maloy W. L., Haynes J. D., Schneider I., Roberts D. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984 Aug 10;225(4662):593–599. doi: 10.1126/science.6204383. [DOI] [PubMed] [Google Scholar]
  21. Edelman R., Hoffman S. L., Davis J. R., Beier M., Sztein M. B., Losonsky G., Herrington D. A., Eddy H. A., Hollingdale M. R., Gordon D. M. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis. 1993 Oct;168(4):1066–1070. doi: 10.1093/infdis/168.4.1066. [DOI] [PubMed] [Google Scholar]
  22. Egan J. E., Hoffman S. L., Haynes J. D., Sadoff J. C., Schneider I., Grau G. E., Hollingdale M. R., Ballou W. R., Gordon D. M. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 1993 Aug;49(2):166–173. doi: 10.4269/ajtmh.1993.49.166. [DOI] [PubMed] [Google Scholar]
  23. Egan J. E., Weber J. L., Ballou W. R., Hollingdale M. R., Majarian W. R., Gordon D. M., Maloy W. L., Hoffman S. L., Wirtz R. A., Schneider I. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science. 1987 Apr 24;236(4800):453–456. doi: 10.1126/science.3551073. [DOI] [PubMed] [Google Scholar]
  24. Etlinger H. M., Caspers P., Matile H., Schoenfeld H. J., Stueber D., Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect Immun. 1991 Oct;59(10):3498–3503. doi: 10.1128/iai.59.10.3498-3503.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Flynn J. L., Weiss W. R., Norris K. A., Seifert H. S., Kumar S., So M. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol. 1990 Dec;4(12):2111–2118. doi: 10.1111/j.1365-2958.1990.tb00572.x. [DOI] [PubMed] [Google Scholar]
  26. Freeman R. R., Holder A. A. Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen. Clin Exp Immunol. 1983 Dec;54(3):609–616. [PMC free article] [PubMed] [Google Scholar]
  27. Fries L. F., Gordon D. M., Richards R. L., Egan J. E., Hollingdale M. R., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):358–362. doi: 10.1073/pnas.89.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Grau G. E., Frei K., Piguet P. F., Fontana A., Heremans H., Billiau A., Vassalli P., Lambert P. H. Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia. J Exp Med. 1990 Nov 1;172(5):1505–1508. doi: 10.1084/jem.172.5.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Grillot D., Valmori D., Lambert P. H., Corradin G., Del Giudice G. Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes. Infect Immun. 1993 Jul;61(7):3064–3067. doi: 10.1128/iai.61.7.3064-3067.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Guerin-Marchand C., Druilhe P., Galey B., Londono A., Patarapotikul J., Beaudoin R. L., Dubeaux C., Tartar A., Mercereau-Puijalon O., Langsley G. A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature. 1987 Sep 10;329(6135):164–167. doi: 10.1038/329164a0. [DOI] [PubMed] [Google Scholar]
  31. Hedstrom R. C., Campbell J. R., Leef M. L., Charoenvit Y., Carter M., Sedegah M., Beaudoin R. L., Hoffman S. L. A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull World Health Organ. 1990;68 (Suppl):152–157. [PMC free article] [PubMed] [Google Scholar]
  32. Herrington D. A., Clyde D. F., Losonsky G., Cortesia M., Murphy J. R., Davis J., Baqar S., Felix A. M., Heimer E. P., Gillessen D. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 1987 Jul 16;328(6127):257–259. doi: 10.1038/328257a0. [DOI] [PubMed] [Google Scholar]
  33. Herrington D., Davis J., Nardin E., Beier M., Cortese J., Eddy H., Losonsky G., Hollingdale M., Sztein M., Levine M. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg. 1991 Nov;45(5):539–547. doi: 10.4269/ajtmh.1991.45.539. [DOI] [PubMed] [Google Scholar]
  34. Hill A. V., Allsopp C. E., Kwiatkowski D., Anstey N. M., Twumasi P., Rowe P. A., Bennett S., Brewster D., McMichael A. J., Greenwood B. M. Common west African HLA antigens are associated with protection from severe malaria. Nature. 1991 Aug 15;352(6336):595–600. doi: 10.1038/352595a0. [DOI] [PubMed] [Google Scholar]
  35. Hill A. V., Elvin J., Willis A. C., Aidoo M., Allsopp C. E., Gotch F. M., Gao X. M., Takiguchi M., Greenwood B. M., Townsend A. R. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature. 1992 Dec 3;360(6403):434–439. doi: 10.1038/360434a0. [DOI] [PubMed] [Google Scholar]
  36. Ho M., Singh B., Looareesuwan S., Davis T. M., Bunnag D., White N. J. Clinical correlates of in vitro Plasmodium falciparum cytoadherence. Infect Immun. 1991 Mar;59(3):873–878. doi: 10.1128/iai.59.3.873-878.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Hoffman S. L., Isenbarger D., Long G. W., Sedegah M., Szarfman A., Waters L., Hollingdale M. R., van der Meide P. H., Finbloom D. S., Ballou W. R. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science. 1989 Jun 2;244(4908):1078–1081. doi: 10.1126/science.2524877. [DOI] [PubMed] [Google Scholar]
  38. Hoffman S. L. Prevention of malaria. JAMA. 1991 Jan 16;265(3):398–399. [PubMed] [Google Scholar]
  39. Holder A. A., Freeman R. R. Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med. 1982 Nov 1;156(5):1528–1538. doi: 10.1084/jem.156.5.1528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Holder A. A., Freeman R. R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature. 1981 Nov 26;294(5839):361–364. doi: 10.1038/294361a0. [DOI] [PubMed] [Google Scholar]
  41. Hollingdale M. R., Nardin E. H., Tharavanij S., Schwartz A. L., Nussenzweig R. S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984 Feb;132(2):909–913. [PubMed] [Google Scholar]
  42. Howard R. J., Handunnetti S. M., Hasler T., Gilladoga A., de Aguiar J. C., Pasloske B. L., Morehead K., Albrecht G. R., van Schravendijk M. R. Surface molecules on Plasmodium falciparum-infected erythrocytes involved in adherence. Am J Trop Med Hyg. 1990 Aug;43(2 Pt 2):15–29. doi: 10.4269/ajtmh.1990.43.15. [DOI] [PubMed] [Google Scholar]
  43. Hui G. S., Tam L. Q., Chang S. P., Case S. E., Hashiro C., Siddiqui W. A., Shiba T., Kusumoto S., Kotani S. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infect Immun. 1991 May;59(5):1585–1591. doi: 10.1128/iai.59.5.1585-1591.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Kaslow D. C., Isaacs S. N., Quakyi I. A., Gwadz R. W., Moss B., Keister D. B. Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus. Science. 1991 May 31;252(5010):1310–1313. doi: 10.1126/science.1925544. [DOI] [PubMed] [Google Scholar]
  45. Khusmith S., Charoenvit Y., Kumar S., Sedegah M., Beaudoin R. L., Hoffman S. L. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science. 1991 May 3;252(5006):715–718. doi: 10.1126/science.1827210. [DOI] [PubMed] [Google Scholar]
  46. Khusmith S., Sedegah M., Hoffman S. L. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun. 1994 Jul;62(7):2979–2983. doi: 10.1128/iai.62.7.2979-2983.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Knapp B., Hundt E., Enders B., Küpper H. A. Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins. Infect Immun. 1992 Jun;60(6):2397–2401. doi: 10.1128/iai.60.6.2397-2401.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Knapp B., Hundt E., Nau U., Küpper H. A. Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol Biochem Parasitol. 1989 Jan 1;32(1):73–83. doi: 10.1016/0166-6851(89)90131-x. [DOI] [PubMed] [Google Scholar]
  49. Knapp B., Nau U., Hundt E. Conservation of antigen components from two recombinant hybrid proteins protective against malaria. Infect Immun. 1993 Mar;61(3):892–897. doi: 10.1128/iai.61.3.892-897.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Kumar S., Miller L. H., Quakyi I. A., Keister D. B., Houghten R. A., Maloy W. L., Moss B., Berzofsky J. A., Good M. F. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature. 1988 Jul 21;334(6179):258–260. doi: 10.1038/334258a0. [DOI] [PubMed] [Google Scholar]
  51. Kwiatkowski D., Cannon J. G., Manogue K. R., Cerami A., Dinarello C. A., Greenwood B. M. Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol. 1989 Sep;77(3):361–366. [PMC free article] [PubMed] [Google Scholar]
  52. Malik A., Egan J. E., Houghten R. A., Sadoff J. C., Hoffman S. L. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3300–3304. doi: 10.1073/pnas.88.8.3300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Mellouk S., Berbiguier N., Druilhe P., Sedegah M., Galey B., Yuan L., Leef M., Charoenvit Y., Paul C., Hoffman S. Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull World Health Organ. 1990;68 (Suppl):52–59. [PMC free article] [PubMed] [Google Scholar]
  54. Mellouk S., Green S. J., Nacy C. A., Hoffman S. L. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol. 1991 Jun 1;146(11):3971–3976. [PubMed] [Google Scholar]
  55. Moreno A., Clavijo P., Edelman R., Davis J., Sztein M., Herrington D., Nardin E. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol. 1991 Oct;3(10):997–1003. doi: 10.1093/intimm/3.10.997. [DOI] [PubMed] [Google Scholar]
  56. Murphy G. S., Basri H., Purnomo, Andersen E. M., Bangs M. J., Mount D. L., Gorden J., Lal A. A., Purwokusumo A. R., Harjosuwarno S. Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993 Jan 9;341(8837):96–100. doi: 10.1016/0140-6736(93)92568-e. [DOI] [PubMed] [Google Scholar]
  57. Nussenzweig R. S., Vanderberg J. P., Most H., Orton C. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature. 1969 May 3;222(5192):488–489. doi: 10.1038/222488a0. [DOI] [PubMed] [Google Scholar]
  58. Nussenzweig R. S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967 Oct 14;216(5111):160–162. doi: 10.1038/216160a0. [DOI] [PubMed] [Google Scholar]
  59. Ockenhouse C. F., Klotz F. W., Tandon N. N., Jamieson G. A. Sequestrin, a CD36 recognition protein on Plasmodium falciparum malaria-infected erythrocytes identified by anti-idiotype antibodies. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3175–3179. doi: 10.1073/pnas.88.8.3175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Patarroyo M. E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L. A., Ponton G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 1988 Mar 10;332(6160):158–161. doi: 10.1038/332158a0. [DOI] [PubMed] [Google Scholar]
  61. Perlmann H., Berzins K., Wahlgren M., Carlsson J., Björkman A., Patarroyo M. E., Perlmann P. Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med. 1984 Jun 1;159(6):1686–1704. doi: 10.1084/jem.159.6.1686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Perrin L. H., Loche M., Dedet J. P., Roussilhon C., Fandeur T. Immunization against Plasmodium falciparum asexual blood stages using soluble antigens. Clin Exp Immunol. 1984 Apr;56(1):67–72. [PMC free article] [PubMed] [Google Scholar]
  63. Perrin L. H., Merkli B., Loche M., Chizzolini C., Smart J., Richle R. Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages. J Exp Med. 1984 Aug 1;160(2):441–451. doi: 10.1084/jem.160.2.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Playfair J. H. Tumor necrosis factor and malaria. Beneficial and harmful aspects. Diagn Microbiol Infect Dis. 1990 Sep-Oct;13(5):435–438. doi: 10.1016/0732-8893(90)90015-n. [DOI] [PubMed] [Google Scholar]
  65. Potocnjak P., Yoshida N., Nussenzweig R. S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med. 1980 Jun 1;151(6):1504–1513. doi: 10.1084/jem.151.6.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Pye D., Edwards S. J., Anders R. F., O'Brien C. M., Franchina P., Corcoran L. N., Monger C., Peterson M. G., Vandenberg K. L., Smythe J. A. Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. Infect Immun. 1991 Jul;59(7):2403–2411. doi: 10.1128/iai.59.7.2403-2411.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Ramasamy R. Studies on glycoproteins in the human malaria parasite Plasmodium falciparum. Identification of a myristilated 45kDa merozoite membrane glycoprotein. Immunol Cell Biol. 1987 Oct;65(Pt 5):419–424. doi: 10.1038/icb.1987.48. [DOI] [PubMed] [Google Scholar]
  68. Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
  69. Rieckmann K. H., Beaudoin R. L., Cassells J. S., Sell K. W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ. 1979;57 (Suppl 1):261–265. [PMC free article] [PubMed] [Google Scholar]
  70. Rieckmann K. H., Carson P. E., Beaudoin R. L., Cassells J. S., Sell K. W. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1974;68(3):258–259. doi: 10.1016/0035-9203(74)90129-1. [DOI] [PubMed] [Google Scholar]
  71. Rieckmann K. H., Davis D. R., Hutton D. C. Plasmodium vivax resistance to chloroquine? Lancet. 1989 Nov 18;2(8673):1183–1184. doi: 10.1016/s0140-6736(89)91792-3. [DOI] [PubMed] [Google Scholar]
  72. Robson K. J., Hall J. R., Jennings M. W., Harris T. J., Marsh K., Newbold C. I., Tate V. E., Weatherall D. J. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature. 1988 Sep 1;335(6185):79–82. doi: 10.1038/335079a0. [DOI] [PubMed] [Google Scholar]
  73. Rodrigues M. M., Cordey A. S., Arreaza G., Corradin G., Romero P., Maryanski J. L., Nussenzweig R. S., Zavala F. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol. 1991 Jun;3(6):579–585. doi: 10.1093/intimm/3.6.579. [DOI] [PubMed] [Google Scholar]
  74. Rogers W. O., Malik A., Mellouk S., Nakamura K., Rogers M. D., Szarfman A., Gordon D. M., Nussler A. K., Aikawa M., Hoffman S. L. Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9176–9180. doi: 10.1073/pnas.89.19.9176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Rogers W. O., Rogers M. D., Hedstrom R. C., Hoffman S. L. Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Mol Biochem Parasitol. 1992 Jul;53(1-2):45–51. doi: 10.1016/0166-6851(92)90005-5. [DOI] [PubMed] [Google Scholar]
  76. Romero P., Maryanski J. L., Corradin G., Nussenzweig R. S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 1989 Sep 28;341(6240):323–326. doi: 10.1038/341323a0. [DOI] [PubMed] [Google Scholar]
  77. Rénia L., Marussig M. S., Grillot D., Pied S., Corradin G., Miltgen F., Del Giudice G., Mazier D. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7963–7967. doi: 10.1073/pnas.88.18.7963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., Foucault C., Chongsuphajaisiddhi T., Druilhe P. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991 Sep;45(3):297–308. doi: 10.4269/ajtmh.1991.45.297. [DOI] [PubMed] [Google Scholar]
  79. Sadoff J. C., Ballou W. R., Baron L. S., Majarian W. R., Brey R. N., Hockmeyer W. T., Young J. F., Cryz S. J., Ou J., Lowell G. H. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science. 1988 Apr 15;240(4850):336–338. doi: 10.1126/science.3281260. [DOI] [PubMed] [Google Scholar]
  80. Sedegah M., Chiang C. H., Weiss W. R., Mellouk S., Cochran M. D., Houghten R. A., Beaudoin R. L., Smith D., Hoffman S. L. Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine. 1992;10(9):578–584. doi: 10.1016/0264-410x(92)90436-n. [DOI] [PubMed] [Google Scholar]
  81. Shaffer N., Grau G. E., Hedberg K., Davachi F., Lyamba B., Hightower A. W., Breman J. G., Phuc N. D. Tumor necrosis factor and severe malaria. J Infect Dis. 1991 Jan;163(1):96–101. doi: 10.1093/infdis/163.1.96. [DOI] [PubMed] [Google Scholar]
  82. Siddiqui W. A., Tam L. Q., Kramer K. J., Hui G. S., Case S. E., Yamaga K. M., Chang S. P., Chan E. B., Kan S. C. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1987 May;84(9):3014–3018. doi: 10.1073/pnas.84.9.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Sim B. K., Orlandi P. A., Haynes J. D., Klotz F. W., Carter J. M., Camus D., Zegans M. E., Chulay J. D. Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol. 1990 Nov;111(5 Pt 1):1877–1884. doi: 10.1083/jcb.111.5.1877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Smythe J. A., Coppel R. L., Brown G. V., Ramasamy R., Kemp D. J., Anders R. F. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5195–5199. doi: 10.1073/pnas.85.14.5195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Smythe J. A., Peterson M. G., Coppel R. L., Saul A. J., Kemp D. J., Anders R. F. Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum. Mol Biochem Parasitol. 1990 Mar;39(2):227–234. doi: 10.1016/0166-6851(90)90061-p. [DOI] [PubMed] [Google Scholar]
  86. Tam J. P., Clavijo P., Lu Y. A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med. 1990 Jan 1;171(1):299–306. doi: 10.1084/jem.171.1.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Taverne J., Bate C. A., Kwiatkowski D., Jakobsen P. H., Playfair J. H. Two soluble antigens of Plasmodium falciparum induce tumor necrosis factor release from macrophages. Infect Immun. 1990 Sep;58(9):2923–2928. doi: 10.1128/iai.58.9.2923-2928.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Valero M. V., Amador L. R., Galindo C., Figueroa J., Bello M. S., Murillo L. A., Mora A. L., Patarroyo G., Rocha C. L., Rojas M. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 1993 Mar 20;341(8847):705–710. doi: 10.1016/0140-6736(93)90483-w. [DOI] [PubMed] [Google Scholar]
  89. Vanderberg J., Nussenzweig R., Most H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil Med. 1969 Sep;134(10):1183–1190. [PubMed] [Google Scholar]
  90. Vermeulen A. N., Ponnudurai T., Beckers P. J., Verhave J. P., Smits M. A., Meuwissen J. H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J Exp Med. 1985 Nov 1;162(5):1460–1476. doi: 10.1084/jem.162.5.1460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Weiss W. R., Berzofsky J. A., Houghten R. A., Sedegah M., Hollindale M., Hoffman S. L. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol. 1992 Sep 15;149(6):2103–2109. [PubMed] [Google Scholar]
  92. Weiss W. R., Mellouk S., Houghten R. A., Sedegah M., Kumar S., Good M. F., Berzofsky J. A., Miller L. H., Hoffman S. L. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med. 1990 Mar 1;171(3):763–773. doi: 10.1084/jem.171.3.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Whitby M., Wood G., Veenendaal J. R., Rieckmann K. Chloroquine-resistant Plasmodium vivax. Lancet. 1989 Dec 9;2(8676):1395–1395. doi: 10.1016/s0140-6736(89)92002-3. [DOI] [PubMed] [Google Scholar]
  94. Wåhlin B., Wahlgren M., Perlmann H., Berzins K., Björkman A., Patarroyo M. E., Perlmann P. Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7912–7916. doi: 10.1073/pnas.81.24.7912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Yoshida N., Nussenzweig R. S., Potocnjak P., Nussenzweig V., Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science. 1980 Jan 4;207(4426):71–73. doi: 10.1126/science.6985745. [DOI] [PubMed] [Google Scholar]
  96. Zhu J., Hollingdale M. R. Structure of Plasmodium falciparum liver stage antigen-1. Mol Biochem Parasitol. 1991 Oct;48(2):223–226. doi: 10.1016/0166-6851(91)90117-o. [DOI] [PubMed] [Google Scholar]
  97. del Portillo H. A., Longacre S., Khouri E., David P. H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4030–4034. doi: 10.1073/pnas.88.9.4030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. ter Kuile F. O., Nosten F., Thieren M., Luxemburger C., Edstein M. D., Chongsuphajaisiddhi T., Phaipun L., Webster H. K., White N. J. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis. 1992 Dec;166(6):1393–1400. doi: 10.1093/infdis/166.6.1393. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES